Navigation Links
Tsunami of Coming Biosimilars Set to Shake up Drug Development Game
Date:1/24/2013

ATLANTA, Jan. 24, 2013 /PRNewswire-USNewswire/ -- The quiet but growing flood of biosimilars ‑ new versions of existing biopharmaceutical drugs ‑ promises to reduce the overall costs of delivering highly effective biotechnology-based medicines, but it's also a game changer for the entire drug development industry akin to the impact generics have had on traditional pharmaceuticals.

(Logo: http://photos.prnewswire.com/prnh/20120628/DC32901LOGO)

BioWorld ‑ the industry's most trusted news service focused on the development of biologics for more than two decades ‑ has identified and profiled 139 key biosimilar developers with >276 biosimilars in their pipelines as well as 25 already approved, according to The Biosimilars Game: A Scorecard for Opportunities, Threats and Critical Strategies.

"The emergence of this new drug development sub-industry translates into opportunities for patient access to very expensive but effective biotech-based therapeutics," said BioWorld's Executive Editor Lynn Yoffee . "But the development of biosimilars brings myriad questions related to drug efficacy ‑ since they are not exact duplicates, just similar ‑ as well as quality, safety and interchangeability with originator products. Perhaps the most complex issue at hand is the lack of global regulatory harmonization."

In the new BioWorld Data report, biosimilars expert and Washington Editor Mari Serebrov provides:

  • In-depth analyses of biosimilar rules and activity in both emerging and regulated markets (15 countries/regions)
  • R&D cost comparisons
  • Data to spot the Big Hitters, including likely targets identified by the FDA, targeted MAbs and other biologics
  • Deal terms for 80 key biosimilar alliances

"Biologics makers need to rethink brand strategies because attempts at product hopping [which delayed generic competition for small-molecule drugs] may not work when biosimilars are available," said Serebrov, author of the new BioWorld Data report.

"As the U.S. continues to wait for its first biosimilar to step up to the plate, global players are already betting on follow-on biologics to be one of the biggest hits in town," Serebrov said. "To earn that star status though, biosimilars will have to show payers the money pretty quickly by delivering the power of biologics at a price economically strapped countries can afford."

BioWorld Today, and its analytical companion, BioWorld Insight, are the biopharmaceutical industry's most respected news sources and have been for more than two decades. All of that information is now leveraged in BioWorld Data, business intelligence for biopharmaceutical executives.

Web Site: http://www.bioworld.com/biosimilars

CONTACT: Lynn Yoffee , Executive Editor, 404-262-5408


'/>"/>
SOURCE BioWorld
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
2. Hospira to Present at Upcoming Investor Conferences
3. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
4. Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events
5. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
6. Elsevier and the Society for Vascular Surgery Announce Forthcoming Launch of Journal of Vascular Surgery: Venous and Lymphatic Disorders
7. Unigenes Oral PTH Phase 2 Proof-of-Concept Data to be Presented at Upcoming Scientific Conferences
8. Overcoming Challenges in Amblyopia Detection using Visual Evoked Potential (VEP)
9. Concordia Study Indicates Obesity is Becoming the Nations Top Health Issue
10. Synergy Pharmaceuticals to Present Scientific Posters at the Upcoming Gastroenterology Society Meetings in the U.S. and Europe
11. MDHI Provides Investor Update -- Provides Business Model Overview -- Discusses Upcoming Profitability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):